UPDATE: Piper Jaffray Initiates Quidel at Overweight on Long-Term Outlook
Piper Jaffray initiated coverage on Quidel (NASDAQ: QDEL) with an Overweight rating and a $26 price target.
Piper Jaffray said, "Our rating is based on Quidel's long-term diversification plan, initially building on the momentum from its Sofia launch and more importantly penetrating the molecular diagnostics market with its pipeline Wildcat instrument. Our $26 price target is based on 4.3x F2013 EV/ revenue, in-line with its small-cap diagnostics peer group."
Quidel closed at $18.17 on Wednesday.
Latest Ratings for QDEL
|Feb 2015||Canaccord Genuity||Maintains||Buy|
|Nov 2014||Canaccord Genuity||Maintains||Buy|
|Jul 2014||JP Morgan||Maintains||Neutral|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.